MedTrace Logo

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT02786901 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2021-01-08

Study results available
· View outcomes & findings →

Summary

Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.

Conditions

  • Cataract
  • Pain
  • Ocular Inflammation

Interventions

DRUG

Loteprednol Etabonate Ophthalmic Gel dosed TID

Gel

DRUG

Loteprednol Etabonate Ophthalmic Gel dosed BID

Gel

DRUG

Vehicle Gel

Gel

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Denise Ramjit · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-06-13
Completion
2017-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786901 on ClinicalTrials.gov